Cargando…

Genetic Modification of Neurons to Express Bevacizumab for Local Anti-angiogenesis Treatment of Glioblastoma

The median survival of glioblastoma multiforme (GBM) approximately 1 yr. Following surgical removal, systemic therapies are limited by the blood-brain barrier. To circumvent this, we developed a method to modify neurons with the genetic sequence for therapeutic monoclonal antibodies using adeno-asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hicks, Martin J., Funato, Kosuke, Wang, Lan, Aronowitz, Eric, Dyke, Jonathan P., Ballon, Douglas J., Havlicek, David F., Frenk, Esther Z., De, Bishnu P., Chiuchiolo, Maria J., Sondhi, Dolan, Hackett, Neil R., Kaminsky, Stephen M., Tabar, Viviane, Crystal, Ronald G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293257/ https://www.ncbi.nlm.nih.gov/pubmed/25501993 http://dx.doi.org/10.1038/cgt.2014.58

Ejemplares similares

Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma
por: Hicks, Martin J., et al.
Publicado: (2016)

Cocaine vaccine dAd5GNE protects against moderate daily and high-dose “binge” cocaine use
por: Havlicek, David F., et al.
Publicado: (2020)

Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease)
por: Sindelar, Miriam, et al.
Publicado: (2018)

Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors
por: Kothari, P., et al.
Publicado: (2017)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Automated Retinal Layer Segmentation in CLN2-Associated Disease: Commercially Available Software Characterizing a Progressive Maculopathy
por: Kovacs, Kyle D., et al.
Publicado: (2021)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Adult Human Glioblastomas Harbor Radial Glia-like Cells
por: Wang, Rong, et al.
Publicado: (2020)

Adult Human Glioblastomas Harbor Radial Glia-like Cells
por: Wang, Rong, et al.
Publicado: (2020)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2020)

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2017)

Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
por: Hata, Nobuhiro, et al.
Publicado: (2019)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
por: García-Romero, N., et al.
Publicado: (2020)

Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)

Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function
por: Orlin, Anton, et al.
Publicado: (2013)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
por: Ahluwalia, Manmeet S., et al.
Publicado: (2023)

Spinal Dissemination of Intracranial Glioblastoma in Bevacizumab Era: a Potential Bevacizumab-induced Mechanism
por: Kaloshi, Gentian, et al.
Publicado: (2014)

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
por: Adilijiang, Alimu, et al.
Publicado: (2019)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010)

Histopathological investigation of glioblastomas resected under bevacizumab treatment
por: Tamura, Ryota, et al.
Publicado: (2016)

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2018)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
por: Vaios, Eugene J, et al.
Publicado: (2020)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application
por: Funakoshi, Yusuke, et al.
Publicado: (2020)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
por: Fack, Fred, et al.
Publicado: (2014)

New Agents Targeting Angiogenesis in Glioblastoma
por: Timotheadou, Eleni
Publicado: (2011)

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
por: Niyazi, Maximilian, et al.
Publicado: (2015)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l690ti9j9qsuu7og1ok6a0qoie